Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies
Journal of Clinical Oncology · 10.05.2025 · 43 (14) · 1695-1705
DOI: 10.1200/jco-24-01933 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.05.2025. Verfasst von Frederick L Locke und 17 weiteren Autor:innen. Beteiligte Einrichtung: Moffitt Cancer Center and Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Off-the-shelf, allogeneic CD19 chimeric antigen receptor (CAR) T-cell products may improve access to treatment versus autologous ones. We report the phase I experience of the allogeneic CD19 CAR T-cell product cemacabtagene ansegedleucel (cema-cel) and its predecessor, ALLO-501, in CD19 CAR T-naïve patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). METHODS In the ALPHA2/ALPHA studies, the safety and efficacy of allogeneic CD19 CAR T cells were evaluated in CD19 CAR T treatment-naïve patients with R/R LBCL. Patients received healthy donor-derived, human leukocyte antigen–unmatched cema-cel/ALLO-501 following a 3-day lymphodepletion regimen of fludarabine (30 mg/m 2 once daily), cyclophosphamide (300 or 500 mg/m 2 once daily), and escalating doses of the anti-CD52 monoclonal antibody, ALLO-647. RESULTS As of September 26, 2024, 33 CD19 CAR T-naïve patients with LBCL (median age, 66 years; median number of previous therapies, 3) received allogeneic CAR T cells. CAR T-cell expansion was observed following infusion, with persistence observed up to 4 months. The overall and complete response (CR) rates were 58% and 42%, respectively; the median duration of response in patients with a CR was 23.1 months. The most common treatment-emergent adverse events were hematologic toxicities. No cases of graft-versus-host disease, immune effector cell–associated neurotoxicity syndrome, or grade ≥3 cytokine release syndrome were reported. CONCLUSION Allogeneic CD19 CAR T cells demonstrated promising overall and durable CR rates with a manageable safety profile in CD19 CAR T-naïve patients with R/R LBCL, supporting additional evaluation of cema-cel in patients with LBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Moffitt Cancer Center and Research Institute, Tampa, FL.
- Mayo Clinic, Phoenix, AZ.
- Colorado Blood Cancer Institute/Sarah Cannon Research Institute, Denver, CO.
- University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, FL.
- University of California, Los Angeles, Los Angeles, CA.
- Banner MD Anderson Cancer Center, Scottsdale, AZ.
ORCID-Profile: Frederick L Locke, Javier L Munoz, Geoffrey P Shouse, Mehdi Hamadani, Olalekan O Oluwole, Miguel-Angel Perales, David B Miklos, Paul W Fisher, John B Le Gall, Sattva S Neelapu
Förderung
- NCI NIH HHS
Zitieren
APA
Locke, F. L., Munoz, J. L., Tees, M. T., Lekakis, L. J., de Vos, S., Nath, R., Stevens, D. A., Malik, S. A., Shouse, G. P., Hamadani, M., Oluwole, O. O., Perales, M. A., Miklos, D. B., Fisher, P. W., Feng, A., Navale, L., Le Gall, J. B., & Neelapu, S. S. (2025). Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. Journal of Clinical Oncology, 43(14), 1695-1705. https://doi.org/10.1200/jco-24-01933
Vancouver
Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, et al. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. Journal of Clinical Oncology. 2025;43(14):1695-1705. doi:10.1200/jco-24-01933
BibTeX
@article{Locke2025,
author = {Locke, Frederick L and Munoz, Javier L and Tees, Michael T and Lekakis, Lazaros J and de Vos, Sven and Nath, Rajneesh and Stevens, Don A and Malik, Shahbaz A and Shouse, Geoffrey P and Hamadani, Mehdi and Oluwole, Olalekan O and Perales, Miguel-Angel and Miklos, David B and Fisher, Paul W and Feng, Amy and Navale, Lynn and Le Gall, John B and Neelapu, Sattva S},
title = {Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {14},
pages = {1695--1705},
doi = {10.1200/jco-24-01933}
}
EUVIMED